qPCR & SNP Genotyping Custom Oligonucleotides – highly sophisticated oligonucleotides – simple PCR primers Oligos in Plates RNA FISH | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Posts Tagged ‘qPCR & SNP Genotyping Custom Oligonucleotides – highly sophisticated oligonucleotides – simple PCR primers Oligos in Plates RNA FISH’

BioMEMS The Market aspects of Oligonucleotide-Chips, Products, Applications and Competition, January 21, 2016

Posted in 3D Printing for Medical Application, Big Data, Bio Instrumentation in Experimental Life Sciences Research, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Informatics, Cell Biology, Cell Biology, Signaling & Cell Circuits, Chemical Genetics, Commercialization, Computational Biology/Systems and Bioinformatics, CRISPR/Cas9 & Gene Editing, Digital HealthCare – biotech & internet joint ventures, DNA repair, Exosomes, FDA Regulatory Affairs, Frontiers in Cardiology and Cardiovascular Disorders, Genetics & Pharmaceutical, Genome Biology, Genomic Expression, Genomic Testing: Methodology for Diagnosis, Intelligent Information Systems, MEMS, Mutagenesis, Proteosome, tagged DNA Sequencing, gene expression, genetics, genome, genomics, Proteomics, qPCR & SNP Genotyping Custom Oligonucleotides - highly sophisticated oligonucleotides - simple PCR primers Oligos in Plates RNA FISH, RNA, THERMO SCIENTIFIC APPLIED BIOSYSTEMS INVITROGEN FISHER SCIENTIFIC UNITY LAB SERVICES on February 2, 2016| Leave a Comment »

BioMEMS The Market aspects of Oligonucleotide-Chips, Products and Applications, Competition, January 21, 2016

Curator: Gérard LOISEAU, ESQ

BioMEMS

The Market aspects of Oligonucleotide-Chips, Products, Applications, Competition

January 21, 2016

2015-2020

The oligonucleotide synthesis market is expected to reach USD 1.918.6Billion at a CAGR of 10.1% by 2020 from USD 1.078.1Billion in 2015.

SOURCE

MARKETSANDMARKETS marketsandmarkets.com/

PLAYERS

Agilent Technologies Inc.
BioAutomation Corp.
Biosearch Technologies
Gen9 Inc.
GenScript Inc.
Illumina Inc.
Integrated DNA Technologies
New England Biolabs Inc.
Nitto Denko Avecia Inc.
OriGene Technologies Inc.
Sigma-Aldrich Corporation
Thermo Fisher Scientific Inc.
TriLink Biotechnologies

Agilent Technologies  CA NYSE :A 

http://www.agilent.com/

Agilent was created as a spin off from Hewlett-Packard Company in 1999.
Agilent Technologies Inc. is engaged in the life sciences, diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company has three business segments:

the life sciences and applied markets business,

the diagnostics and genomics business, and

the Agilent Cross Lab business

The Company’s life sciences and applied markets business segment brings together the Company’s analytical laboratory instrumentation and informatics.
The Company’s diagnostics and genomics business segment consists of three businesses: the Dako business, the genomics business and the nucleic acid solutions business.
The Company’s Agilent Cross Lab business segment combines its analytical laboratory services and consumables business

SOURCE

http://reuters.com/

PRODUCTS AND SERVICES

https://www.agilent.com/en-us/default#collapse-0

October 09, 2015 03:21 PM Eastern Daylight Time
CARPINTERIA, Calif.–(BUSINESS WIRE)–Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. Food and Drug Administration has approved a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO^® (nivolumab) for patients with non-squamous NSCLC.

SOURCE

BUSINESS WIRE busibesswire.com/

BioAutomation Corp.   TX 

http://bioautomation.com/

PRODUCTS AND SERVICES

DNA and RNA synthesis reagents for the MerMades

Note: The MerMade 192E Oligonucleotide synthesizer is designed to synthesize DNA, RNA & LNA oligonucleotides in a column format

PARTNERSHIPS

HONGENE BIOTECH : BIOAUTOMATION is the exclusive distributor for the Americas
EMD MILLIPORE
BIOSEARCH TECHNOLOGIES

DISTRIBUTORS

LINK TECHNOLOGIES : UK
AME BIOSCIENCE : UK
BOSUNG SCIENCE : KOREA
DNA CHEM : CHINA
WAKO : JAPAN
ACE PROBE : INDIA

SOURCE

bioautomation.com/

Biosearch Technologies  CA 

http://biosearchtech.com/

PRODUCTS

qPCR & SNP Genotyping
Custom Oligonucleotides
– highly sophisticated oligonucleotides
– simple PCR primers
Oligos in Plates
RNA FISH
Synthesis Reagents
Immunochemicals
Primers
Probes
Large-Scale Synthesis Oligos
Intermediate-Scale Synthesis Oligos

SERVICES

GMP & Commercial Services
OEM & Kit Manufacturing
qPCR Design Collaborations

DISTRIBUTORS

SOURCE

biosearchtech.com/

Gen9 Inc.  MA  

http://www.gen9bio.com/

PRODUCTS

Gen9 is building on advances in synthetic biology to power a scalable fabrication capability that will significantly increase the world’s capacity to produce DNA content. The privately held company’s next-generation gene synthesis technology allows for the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods on the market. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels.

SERVICES

Synthetic Biology
Gene Synthesis Services
Variant Libraries
Gene Sequence Design Services

INVESTORS

Agilent Technologies : Private Equity
CAMBRIDGE, Mass. and SANTA CLARA, Calif. — April 24, 2013 —Gen9 Receives $21 Million Strategic Investment from Agilent Technologies

SOURCE

gen9bio.com/

GenScript Inc.  NJ  

http://www.genscript.com/

GenScript is the largest gene synthesis provider in the USA

GenScript Corporation, a biology contract research organization, provides biological research and drug discovery services to pharmaceutical companies, biotech firms, and research institutions in the United States, Europe, and Japan. It offers bio-reagent, custom molecular biology, custom peptide, protein production, custom antibody production, drug candidates testing, assay development and screening, lead optimization, antibody drug development, gene synthesis, and assay-ready cell line production services.

The company also offers molecular biology, peptide, protein, immunoassay, chemicals, and cell biology products. It offers its products through distributors in Tokyo, Japan; and Seoul, Korea. GenScript Corporation has a strategic partnership with Immunologix, Inc. The company was founded in 2002 and is based in Piscataway, New Jersey. It has subsidiaries in France, Japan, and China.

Note: As of October 24, 2011, Immunologix, Inc. was acquired by Intrexon Corporation. Immunologix, Inc. develops and produces antibody-based therapeutics for various biological targets. It produces human monoclonal antibodies against viral, bacterial, and tumor antigens, as well as human auto antigens.

Intrexon Corporation, founded in 1998, is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment and Consumer sectors to create biologically based products that improve quality of life and the health of the planet.

PRODUCTS AND SERVICES

Gene synthesis
Antibody services
Protein Services
Peptide services

INVESTORS 

Note: The Balloch Group (‘TBG’) was established in 2001 by Howard Balloch (Canada‘s ambassador to China from 1996 to 2001). TBG has since grown from a market-entry consultancy working with North American clients in China to a leading advisory and merchant banking firm serving both domestic Chinese companies and multinational corporations. TBG was ranked as the number one boutique investment bank in China by ChinaVenture in 2008.

Kleiner, Perkins, Caufield and Byers

Illumina Inc. CA 

http://illumina.com/

Monica Heger : SAN FRANCISCO (GenomeWeb) – Illumina today announced two new next-generation sequencing platforms, a targeted sequencing system called MiniSeq and a semiconductor sequencer that is still under development.

Illumina disclosed the initiatives during a presentation at the JP Morgan Healthcare conference held here today. During the presentation, Illumina CEO Jay Flatley also announced a new genotyping array called Infinium XT; a partnership with Bio-Rad to develop a single-cell sequencing workflow; preliminary estimates of its fourth-quarter 2015 revenues; and an update on existing products. The presentation followed the company’s announcement on Sunday that it has launched a new company called Grail to develop a next-generation sequencing test for early cancer detection from patient blood samples.

The MiniSeq system, which is based on Illumina’s current sequencing technology, will begin shipping early this quarter and has a list price of $49,500. It can perform a variety of targeted DNA and RNA applications, from single-gene to pathway sequencing, and promises “all-in” prices, including library prep and sequencing, of $200 to $300 per sample, Flatley said during the JP Morgan presentation.

SOURCES

https://www.genomeweb.com/sequencing-technology/illumina-unveils-mini-targeted-sequencer-semiconductor-sequencing-project-jp

http://investor.biospace.com/biospace/quote?Symbol=ILMN

PRODUCTS AND SERVICES

Mid to large scale manufacturing assets
Analytical Labs
Pre-clinical
Clinical
Launched products

COMPETITORS

https://finance.yahoo.com/q/co?s=ILMN+Competitors Tue, Feb 2, 2016, 2:16pm EST – US Markets

	ILMN	PVT1	AFFX	LMNX	Industry
Market Cap:	22.75B	N/A	1.13B	835.66M	134.14M
Employees:	3,700	10,000	1,200	745	45.00
Qtrly Rev Growth (yoy):	0.14	N/A	-0.01	0.07	0.18
Revenue (ttm):	2.14B	3.80B¹	357.74M	235.37M	8.47M
Gross Margin (ttm):	0.73	N/A	0.63	0.71	0.58
EBITDA (ttm):	770.84M	N/A	46.64M	52.99M	-12.31M
Operating Margin (ttm):	0.30	N/A	0.08	0.17	-1.62
Net Income (ttm):	510.36M	430.90M¹	11.22M	39.29M	N/A
EPS (ttm):	3.42	N/A	0.13	0.93	-0.34
P/E (ttm):	45.43	N/A	104.40	20.91	25.33
PEG (5 yr expected):	2.68	N/A	4.66	0.55	N/A
P/S (ttm):	10.87	N/A	3.13	3.45	13.65

Pvt1 = Life Technologies Corporation (privately held)

AFFX = Affymetrix Inc.

LMNX = Luminex Corporation

Integrated DNA Technologies (IDT) IOWA + CA

http://www.com/

Integrated DNA Technologies, Inc. (IDT), the global leader in nucleic acid synthesis, serving all areas of life sciences research and development, offers products for a broad range of genomics applications. IDT’s primary business is the production of custom, synthetic nucleic acids for molecular biology applications, including qPCR, sequencing, synthetic biology, and functional genomics. The company manufactures and ships an average of 44,000 custom nucleic acids per day to more than 82,000 customers worldwide. For more information, visit idtdna.com.

PRODUCTS AND SERVICES

https://eu.idtdna.com/site

DNA & RNA Synthesis
Custom DNA Oligos 96- & 384-Well Plates Ultramer Oligos Custom RNA Oligos SameDay Oligos HotPlates ReadyMade Primers Oligo Modifications Freedom
Dyes GMP for Molecular Diagnostics Large Scale Oligo Synthesis

Note : Skokie, IL – December 1, 2015. Integrated DNA Technologies Inc. (“IDT”), the global leader in custom nucleic acid synthesis, has entered into a definitive agreement to acquire the oligonucleotide synthesis business of AITbiotech Pte. Ltd. in Singapore (“AITbiotech”). With this acquisition, IDT expands its customer base across Southeast Asia making it possible for these additional customers to now have access to its broad range of products for genomic applications. AITbiotech will continue operations in its other core business areas.

New England Biolabs Inc.  MA  

http://www.neb.com/

PRODUCTS AND SERVICES

Restriction Endonucleases
PCR, Polymerases & Amplification Technologies
DNA Modifying Enzymes
Library Preparation for Next Generation Sequencing
Nucleic Acid Purification
Markers & Ladders

RNA Reagents
Gene Expression
Cellular Analysis

SOURCE

neb.com/

Nitto Denko Avecia Inc.  MA 

http://avecia.com/

With over 20 years of experience in oligonucleotide development and production, and over 1000 sequences manufactured, Avecia has played an integral role in the advancing oligo therapeutic market. Our mission is to continue to build value for our customers, as they progress through drug development into commercialization. And as a member of the Nitto Denko Corporation (nitto.com), Avecia is committed to the future of the oligonucleotide market. We are driven by innovative ideas and flexible solutions, designed to provide our customers with the best in service, quality, and technology.

SOURCE

http://avecia.com/

Note : 1918 Nitto Electric Industrial Co., Ltd. forms in Ohsaki, Tokyo, to produce electrical insulating materials in Japan.

2011 Acquires Avecia Biotechnology Inc. in the U.S.A.

OriGene Technologies Inc.  CA

http://www.com/

OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products for pharmaceutical, biotechnology, and academic research applications. The company offers cDNA clones, including TrueORF cDNA, viral ORF, destination vectors, TrueClones (human), TrueClones (mouse), organelle marker plasmids, MicroRNA tools, mutant and variant clones, plasmid purification kits, transfection reagents, and gene synthesis service; and HuSH shRNA, siRNA, miRNA, qPCR reagents, plasmid purification products, transfection reagents, PolyA+ and total RNA products, first-strand cDNA synthesis, and CRISPR/Cas9 genome products. It also provides proteins and lysates, such as purified human proteins, over-expression cell lysates, mass spectrometry standard proteins, and protein purification reagents; UltraMAB IHC antibodies, TrueMAB primary antibodies, anti-tag and fluorescent proteins, ELISA antibodies, luminex antibodies, secondary antibodies, and controls and others; and anatomic pathology products, including IHC antibodies, detection systems, and IHC accessories

The company offers luminex and ELISA antibody pairs, autoantibody profiling arrays, ELISA kits, cell assay kits, assay reagents, custom development, and fluorogenic cell assays; TissueFocus search tools; tissue sections; tissue microarrays, cancer protein lysate arrays, TissueScan cDNA arrays, tissue blocks, and quality control products, as well as tissue RNA, DNA, and protein lysates; and lab essentials. Its research areas include cancer biomarker research, RNAi, pathology IHC, stem cell research, ion channels, and protein kinase products. The company provides gene synthesis and molecular biology services, genome editing, custom cloning, custom shRNA, purified protein, monoclonal antibody development, and assay development. It sells its products through distributors worldwide, as well as online. OriGene Technologies, Inc. was incorporated in 1995 and is based in Rockville, Maryland.

SOURCE

http://BLOOMBERG.com

PRODUCTS AND SERVICES

cDNA Clones Human, mouse, rat Expression validated
RNAi shRNA, siRNA microRNA & 3’UTR clones
Gene Synthesis Codon optimization Variant libraries
Real-time PCR Primer pairs, panels SYBR green reagents
Lab Essentials DNA/RNA purification kits Transfection reagents
Anatomic Pathology UltraMAB antibodies Specificity validated
Recombinant Proteins 10,000 human proteins from mammalian system
Antibodies TrueMAB primary antibodies Anti-tag antibodies
Assays and Kits ELISA & Luminex antibodies Autoantibody Profiling Array
Cancer & Normal Tissues Pathologist verified gDNA, RNA, sections, arrays

SOURCE

origene.com/

Sigma-Aldrich Corporation  MI  

http://www.sigmaaldrich.com/

Louis, MO – November 18, 2015 Merck KGaA, Darmstadt, Germany, Completes Sigma-Aldrich Acquisition

Merck KGaA today announced the completion of its $17 billion acquisition of Sigma-Aldrich, creating one of the leaders in the $130 billion global industry to help solve the toughest problems in life science.

Press Release: 18-Nov-2015

Letter to our Life Science Customers from Dr. Udit Batra

The life science business of Merck KGaA, Darmstadt, Germany brings together the world-class products and services, innovative capabilities and exceptional talent of EMD Millipore and Sigma-Aldrich to create a global leader in the life science industry.

“Everything we do starts with our shared purpose – to solve the toughest problems in life science by collaborating with the global scientific community.

This combination is built on complementary strengths, which will enable us to serve you even better as one organization than either company could alone.

This means providing a broader portfolio with a catalog of more than 300,000 products, including many of the most respected brands in the industry, greater geographic reach, and an unmatched combination of industry-leading capabilities.”

PRODUCTS AND SERVICES

http://www.sigmaaldrich.com/configurator/servlet/DesignCenter?btnOpen_0.x=1

http://www.sigmaaldrich.com/content/dam/sigma-aldrich/common/quality-products.jpg

Thermo Fisher Scientific Inc.  MA  NYSE :TMO 

http://thermofisher.com/

 Thermo Fisher Scientific Inc. is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments, provides instruments, consumables, software and services that are used in the laboratory; Specialty Diagnostics, offers diagnostic test kits, reagents, culture media, instruments and associated products, and Laboratory Products and Services, offers self-manufactured and sourced products for the laboratory.

SOURCE

http://REUTERS.com

PRODUCTS AND SERVICES

Oligos Value – Standard – Plate
Primers
Probes
Nucleotides

BRANDS

THERMO SCIENTIFIC
APPLIED BIOSYSTEMS
INVITROGEN
FISHER SCIENTIFIC
UNITY LAB SERVICES

PARTNERSHIPS

AFFYMETRIX : NASDAQ : AFFX : affymetrix.com/

WALTHAM, Mass. & SANTA CLARA, Calif.–(BUSINESS WIRE)–Jan. 8, 2016– Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and Affymetrix Inc. (NASDAQ:AFFX), a leading provider of cellular and genetic analysis products, today announced that their boards of directors have unanimously approved Thermo Fisher’s acquisition of Affymetrix for $14.00 per share in cash. The transaction represents a purchase price of approximately $1.3 billion.

SOURCE

http://BUSINESSWIRE.com

TriLink Biotechnologies  CA  

http://www.com/

PRODUCTS

Oligonucleotides